Breaking News
May 20, 2018 - Developmental psychotherapy aims at helping antisocial adolescents become responsible adults
May 20, 2018 - People with OCD process emotions differently than their unaffected siblings
May 20, 2018 - Interfering with enzyme’s movement may be new approach for developing of anti-cancer drugs
May 20, 2018 - Prestroke and poststroke oral anticoagulation therapy in AF patients
May 20, 2018 - Why drug users prefer heroin at home, but cocaine while out
May 20, 2018 - Gene therapy that reverses blindness in dogs could also help treat humans
May 20, 2018 - Opioid-Related Payments Linked to Increase in Opioid Rx
May 20, 2018 - Phone apps push people to take their pills
May 20, 2018 - Backbreaking Work May Shorten Men’s Lives
May 20, 2018 - Harsher drug laws won’t stop violence, argues former police chief
May 20, 2018 - Cognitive decline in dementia is not reduced by exercise
May 20, 2018 - Detecting breast cancer with non-invasive ‘disease screening pill’
May 20, 2018 - Simple treatment may minimize hearing loss triggered by loud noises
May 20, 2018 - Alignment of mother and offspring body clock could prevent diseases such as heart disease and obesity
May 20, 2018 - New commercial data warehouse for life sciences
May 20, 2018 - Practice Intervention Targeting IV Opioids May Cut Exposure
May 20, 2018 - New study provides insight into blood signatures of inflammation
May 20, 2018 - Scientists make breakthrough discovery about vitamin B12
May 20, 2018 - What Causes Cancer? Misconceptions Abound
May 20, 2018 - Proper burial of dead cells limits inflammation
May 20, 2018 - Study offers novel solution to suppress metastatic spread of deadly breast cancer
May 20, 2018 - Perspectives of patients and caregivers on care transitions
May 20, 2018 - Guidelines for weight gain in pregnancy should be changed for underweight and very obese women
May 20, 2018 - Researchers transplant retinal sheets derived from human embryonic stem cells in retinal degeneration mouse models
May 20, 2018 - U.S. military personnel at greater risk for skin cancer than general population
May 20, 2018 - Your immune system holds the line against repeat invaders, thanks to this molecule
May 20, 2018 - Between death and deportation
May 20, 2018 - Developing a High Throughput Mass Spectrometry Platform for Drug Discovery
May 19, 2018 - New project aims to increase awareness among hospital clinicians of non-beneficial treatment at end-of-life
May 19, 2018 - Automated bone scan index offers accurate, speedy prognostic information about prostate cancer
May 19, 2018 - Rutgers Cancer Institute nurses research various topics to enhance patient experience
May 19, 2018 - Computer models provide valuable insight to structure and function of Ebola, Zika viruses
May 19, 2018 - Study exposes key tactic used by deadly fungus
May 19, 2018 - Bacterial signals are crucial to development of pre-leukemic myeloproliferation, study shows
May 19, 2018 - Global experts identify key issues in supporting children with brain injuries transition back to school
May 19, 2018 - Social connections may protect black men who have sex with men from acquiring HIV
May 19, 2018 - Study IDs Factors Linked to Quality of Life With Dementia
May 19, 2018 - Potassium — Consumer
May 19, 2018 - HIV-1 viruses transmitted at birth are resistant to antibodies in mother’s blood
May 19, 2018 - Some water pitchers are much better at removing toxins, shows research
May 19, 2018 - Scientists discover how unusually long strands of RNA help colon cancer cells avoid death
May 19, 2018 - International study finds viable treatment option for people with mild asthma
May 19, 2018 - Mayo discovery could enable development of personalized ovarian, brain cancer treatments
May 19, 2018 - ‘Superbug’ Surfaces at Poultry Farm in China
May 19, 2018 - UCLA-designed program helps former HIV-positive inmates maintain health after release from jail
May 19, 2018 - New blood test could help avoid more than 40% of prostate biopsies, study finds
May 19, 2018 - Macrophages play key role in maintaining stem cell niche of mammary gland
May 19, 2018 - Ferritin Blood Test: MedlinePlus Lab Test Information
May 19, 2018 - Prolonged exposure to air pollution leads to genetic changes in rat brains, study finds
May 19, 2018 - Scientists identify new potential target to combat acute myeloid leukemia
May 19, 2018 - Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer
May 19, 2018 - MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 19, 2018 - Research shows that sexual activity and emotional closeness are unrelated to the rate of cognitive decline
May 19, 2018 - Nuffield Council on Bioethics outlines ethical issues arising from use of AI in healthcare
May 19, 2018 - Pancreatic cancer patients with BRCA1 or BRCA2 mutations fare better on platinum-based chemotherapy
May 19, 2018 - Tradeshow Talks with nal von minden Ltd
May 19, 2018 - Chemist begins new project to develop carbohydrate mimics to assist cancer therapies
May 19, 2018 - Healthy Lifestyle for Healthy Older Adults
May 19, 2018 - Epstein-Barr virus linked to seven serious diseases
May 19, 2018 - Biochemists isolate protein supercomplex from bacteria that generates voltage
May 19, 2018 - Mindfulness-based Stress Management Course for cancer survivors
May 19, 2018 - Simple screening tool can help identify people at increased risk for dementia
May 19, 2018 - Many gay and bisexual teenage boys use adult hookup apps to connect with friends, partners
May 19, 2018 - Maternal Exposure to Polluted Air Tied to Elevated Child BP
May 19, 2018 - Experimental drug extends survival in progeria
May 19, 2018 - FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies
May 19, 2018 - Brazilians with less education more likely to perceive as being in poor health
May 19, 2018 - Experts available to discuss subjects related to Ebola virus
May 19, 2018 - Opioid Makers’ Perks to Docs Tied to More Prescriptions
May 19, 2018 - AI detects patterns of gut microbes for cholera risk
May 19, 2018 - Researcher develops small molecules that inhibit derailment of gene expression in cancer
May 19, 2018 - Study brings fresh insights into biology of malaria parasite
May 19, 2018 - Microglia may play key role in slowing progression of prion diseases, research suggests
May 19, 2018 - Safety program successfully reduces SSIs in patients undergoing colorectal operations
May 19, 2018 - Clinical study supports usual medical care plus chiropractic care for low back pain
May 19, 2018 - Vermont legislators pass a drug importation law. So what?
May 19, 2018 - Trump proposes cutting planned parenthood funds. What does that mean?
May 19, 2018 - Cognitive training intervention reduces gait freezing in Parkinson’s patients, study shows
May 19, 2018 - Clinical trial begins enrollment to test safety of experimental MERS treatments
May 19, 2018 - Scientists disrupt two enzymes to shrink cancer cells
Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

image_pdfDownload PDFimage_print

Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

CHARLESTON, S.C. December 20, 2017 — Aeterna Zentaris Inc. (NASDAQ and TSX: AEZS), a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Macrilen (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD). The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe.

“Aeterna Zentaris is proud of our commitment to patients with suspected AGHD and to the endocrinology community who we are confident will welcome an easier safe and effective oral diagnostic tool,” said Michael V. Ward, Chief Executive Officer, Aeterna Zentaris. “In the absence of an FDA-approved diagnostic test for AGHD, Macrilen fills an important gap and addresses a medical need for a convenient test that will better serve patients and health providers.”

Macrilen (macimorelin) stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. Stimulated growth hormone levels are measured in four blood samples over ninety minutes after oral administration of Macrilen (macimorelin) for the assessment of growth hormone deficiency (“GHD”). Prior to the approval of Macrilen (macimorelin), the historical gold standard for evaluation of AGHD was the insulin tolerance test (“ITT”), an intravenous test requiring many blood draws over several hours. The ITT procedure is inconvenient for patients and medical practitioners and may contraindicate in patients, such as those with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain an accurate result.

“Clinical studies have demonstrated that growth hormone stimulation testing for AGHD with oral Macrilen (macimorelin) is reliable, well-tolerated, reproducible, safe and a much simpler test to conduct than currently available options,” said Kevin Yuen, MD, clinical investigator and neuroendocrinologist, Barrow Neurological Institute, and medical director of the Barrow Neuroendocrinology Clinic, Phoenix, Arizona. “The availability of Macrilen (macimorelin) will greatly relieve the burden of endocrinologists in reliably and accurately diagnosing AGHD.”

Aeterna Zentaris intends to make Macrilen (macimorelin) available commercially in the United States during the first quarter of 2018.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing Macrilen™ (macimorelin). On November 27, 2017 Aeterna Zentaris announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of AGHD was accepted by the European Medicines Agency (EMA) for regulatory review. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the U.S. Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, which reflect our current expectations regarding future events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “would,” “could,” “may,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known risks and uncertainties, many of which are discussed under the caption “Key Information – Risk Factors” in our most recent Annual Report on Form 20-F filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission (“SEC”). Such statements include, but are not limited to, statements about the timing of, and prospects for, regulatory approval and commercialization of our product candidates, statements about the status of our efforts to establish a commercial operation and to obtain the right to promote or sell products that we did not develop and estimates regarding our capital requirements and our needs for, and our ability to obtain, additional financing. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, our now heavy dependence on the success of Macrilen™ (macimorelin) and the continued availability of funds and resources to successfully launch the product, and, more generally, uncertainties related to the regulatory process, the rejection of the MMA by the EMA and the ability of the Company to efficiently commercialize Macrilen™ (macimorelin), the degree of market acceptance of Macrilen™ (macimorelin), our ability to obtain necessary approvals from the relevant regulatory authorities to enable us to use the desired brand names for our products, the impact of securities class action litigation, the litigation involving two former officers of the Company, or other litigation, on our cash flow, results of operations and financial position; any evaluation of potential strategic alternatives to maximize potential future growth and stakeholder value may not result in any such alternative being pursued, and even if pursued, may not result in the anticipated benefits, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the applicable Canadian securities regulators and the SEC for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Source: Aeterna Zentaris Inc.

Posted: December 2017

Related Articles:

  • NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date – July 18, 2017
  • Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults – June 30, 2017
  • Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 – March 30, 2017
  • Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen – February 13, 2017
  • Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen – October 26, 2016
  • Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen in AGHD – April 13, 2015
  • FDA Issues Complete Response Letter for Macrilen (macimorelin) NDA in Adult Growth Hormone Deficiency – November 6, 2014
  • Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA – January 6, 2014
  • Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD – November 5, 2013

Macrilen (macimorelin) FDA Approval History

Tagged with:

About author

Related Articles